Bystander-mediated genomic instability after high LET radiation in murine primary haemopoietic stem cells

Author(s):  
Deborah A. Bowler ◽  
Stephen R. Moore ◽  
Denise A. Macdonald ◽  
Sharon H. Smyth ◽  
Peter Clapham ◽  
...  
2018 ◽  
Vol 7 (7) ◽  
pp. 513-520 ◽  
Author(s):  
Rutulkumar Patel ◽  
Yulan Qing ◽  
Lucy Kennedy ◽  
Yan Yan ◽  
John Pink ◽  
...  

2003 ◽  
Vol 79 (1) ◽  
pp. 27-34 ◽  
Author(s):  
J. McIlrath ◽  
S. A. Lorimore ◽  
P. J. Coates ◽  
E. G. Wright

Oncogene ◽  
2003 ◽  
Vol 22 (45) ◽  
pp. 7034-7042 ◽  
Author(s):  
Eric J Hall ◽  
Tom K Hei

2003 ◽  
Vol 79 (1) ◽  
pp. 27-34 ◽  
Author(s):  
J. McIlrath ◽  
S. A. Lorimore ◽  
P. J. Coates ◽  
E. G. Wright

1996 ◽  
Vol 24 (4) ◽  
pp. 539S-539S ◽  
Author(s):  
SM Clutton ◽  
KMS Townsend ◽  
JD Ansell ◽  
EG Wright

2020 ◽  
Vol 21 (21) ◽  
pp. 8151
Author(s):  
Sharda Kumari ◽  
Shibani Mukherjee ◽  
Debapriya Sinha ◽  
Salim Abdisalaam ◽  
Sunil Krishnan ◽  
...  

Radiation therapy (RT), an integral component of curative treatment for many malignancies, can be administered via an increasing array of techniques. In this review, we summarize the properties and application of different types of RT, specifically, conventional therapy with x-rays, stereotactic body RT, and proton and carbon particle therapies. We highlight how low-linear energy transfer (LET) radiation induces simple DNA lesions that are efficiently repaired by cells, whereas high-LET radiation causes complex DNA lesions that are difficult to repair and that ultimately enhance cancer cell killing. Additionally, we discuss the immunogenicity of radiation-induced tumor death, elucidate the molecular mechanisms by which radiation mounts innate and adaptive immune responses and explore strategies by which we can increase the efficacy of these mechanisms. Understanding the mechanisms by which RT modulates immune signaling and the key players involved in modulating the RT-mediated immune response will help to improve therapeutic efficacy and to identify novel immunomodulatory drugs that will benefit cancer patients undergoing targeted RT.


1989 ◽  
Vol 117 (2) ◽  
pp. 351 ◽  
Author(s):  
Robert W. Atcher ◽  
Angelo Russo ◽  
William G. DeGraff ◽  
Mark Moore ◽  
David J. Grdina ◽  
...  
Keyword(s):  

2008 ◽  
Vol 170 (6) ◽  
pp. 794-802 ◽  
Author(s):  
Torsten Groesser ◽  
Brian Cooper ◽  
Bjorn Rydberg

Sign in / Sign up

Export Citation Format

Share Document